Our Pricing

Published on: June 03, 2026

Securing a wegovy online prescription discount code uk service has become simpler with registered online pharmacies offering transparent pricing and clinical consultations. At Cured Pharmacy, patients access genuine UK-licensed Wegovy (semaglutide) from £79.00 with code WEIGHTLOSSNEW, supported by a free assessment from our UK-registered prescribers.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite by acting on brain receptors that control hunger and satiety.

In the landmark STEP 1 clinical trial, participants using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication slows gastric emptying and reduces energy intake, helping patients feel fuller for longer periods between meals.

As a once-weekly subcutaneous injection, Wegovy offers a convenient dosing schedule that many patients find easier to maintain than daily medications. The treatment follows a gradual dose escalation protocol over 16-20 weeks to minimise gastrointestinal side effects whilst optimising therapeutic response [2].

Wegovy Online Prescription Process at Cured Pharmacy

The wegovy online prescription discount code uk pathway at Cured Pharmacy follows strict regulatory standards whilst offering competitive pricing. After your prescriber approves treatment, you'll receive confirmation with transparent pricing before any payment is processed.

We dispense only genuine UK-licensed Wegovy pens sourced directly from authorised wholesalers. Each pen arrives in discreet packaging with full patient information leaflets and injection guidance. Our pharmacy team remains available on (+44) 116 4646009 for any questions about administration or side effects.

Clinical Assessment Requirements

Every Wegovy prescription requires a thorough clinical assessment by a UK-registered prescriber, as mandated by MHRA regulations. Our online consultation takes under 3 minutes and covers your medical history, current medications, weight management goals, and any contraindications to semaglutide therapy.

Our clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews each assessment individually. We check for conditions that may affect suitability, including history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease [2].

Using Your WEIGHTLOSSNEW Discount Code

The WEIGHTLOSSNEW discount code applies automatically when you start your assessment for Wegovy through our weight loss category. This promotional code reduces the standard price, bringing Wegovy from £79.00 down to £79.00 for eligible patients.

Unlike some online pharmacies that display prices only after consultation, Cured Pharmacy shows transparent upfront pricing so you know exact costs before beginning your assessment. The discount applies to your first prescription, helping make this evidence-based treatment more accessible to UK patients seeking effective weight management solutions.

Dose Escalation and Treatment Duration

Wegovy treatment begins at 0.25mg weekly for the first four weeks, then increases gradually through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [2]. This stepwise approach significantly reduces the incidence of nausea and vomiting compared to starting at higher doses.

Most patients continue treatment for at least 12-16 months to achieve optimal weight loss, though duration varies based on individual response and clinical goals. Your prescriber will schedule regular reviews to monitor progress, assess tolerability, and adjust treatment as needed.

Wegovy vs Other Weight Loss Treatments Available in the UK

Several prescription weight loss medications are licensed in the UK, each working through different mechanisms. Wegovy (semaglutide) is a GLP-1 receptor agonist, whilst alternatives include dual-pathway medications and lipase inhibitors with distinct efficacy profiles.

Clinical trial data helps inform treatment selection. The STEP programme demonstrated semaglutide's superior weight loss compared to earlier GLP-1 medications, whilst newer dual GIP/GLP-1 agonists have shown even greater reductions in some studies [3]. Your prescriber considers your medical history, previous treatment responses, and individual risk factors when recommending the most appropriate option.

Oral medications like orlistat work by blocking fat absorption rather than affecting appetite hormones, typically producing more modest weight reductions of 5-10% [4]. Injectable GLP-1 therapies generally demonstrate greater efficacy but require patient comfort with self-injection and acceptance of potential gastrointestinal side effects during initial weeks.

Common Side Effects and How to Manage Them

Less common but serious side effects require immediate medical attention: severe abdominal pain that radiates to the back (possible pancreatitis), rapid heartbeat, persistent vomiting leading to dehydration, or changes in vision [2]. Our clinical team provides comprehensive safety information with every prescription and remains available to address concerns throughout your treatment journey.

Some patients experience injection site reactions such as redness, itching, or mild swelling. Rotating injection sites between the abdomen, thigh, and upper arm helps prevent these localised reactions. The pre-filled Wegovy pen is designed for ease of use, and our patient information materials include step-by-step injection guidance.

Gastrointestinal Symptoms

The most frequently reported side effects of Wegovy are gastrointestinal: nausea (44% of patients in STEP 1), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These symptoms typically peak during dose escalation phases and diminish over time as your body adapts to the medication.

Practical strategies to minimise discomfort include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week. If symptoms persist or worsen, contact your prescriber—they may recommend slowing the dose escalation or temporarily maintaining your current dose.

Who Can Use Wegovy and Important Contraindications

If you have a history of pancreatitis, diabetic retinopathy, or kidney disease, your prescriber will assess whether Wegovy is appropriate or whether closer monitoring is needed. The medication may interact with other drugs, particularly insulin and sulfonylureas in diabetic patients, potentially increasing hypoglycaemia risk [2].

Women of childbearing potential should use effective contraception during treatment and discontinue Wegovy at least 2 months before a planned pregnancy, as animal studies have shown potential reproductive risks [2]. Our prescribers review all these factors during your assessment to ensure Wegovy is both safe and appropriate for your individual circumstances.

Eligibility Criteria for Wegovy Prescriptions

NICE guidelines support the use of GLP-1 receptor agonists like Wegovy for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Your prescriber will calculate your BMI and review your medical history during the online consultation.

Wegovy is not suitable for everyone. Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous serious hypersensitivity to semaglutide, and pregnancy or breastfeeding [2]. Patients with severe gastrointestinal disease, including inflammatory bowel disease, should discuss risks and benefits carefully with their prescriber.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). Retrieved from https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.